

Supplementary Table 2. Sensitivity analysis: fully adjusted HRs of selected study endpoints for different SGLT2i treatment strategies (main analysis and IPTW analysis).

		Main analysis			IPTW analysis			
		Exposure	HR*	95% CI	p value	HR [†]	95% CI	p value
Mortality	ITT	Non-initiator	1.0			1.0		
		SGLT2i initiator	0.56	0.49–0.63	<0.01	0.59	0.45–0.77	<0.01
	OT	Non-initiator	1.0			1.0		
		SGLT2i initiator	0.34	0.27–0.42	<0.01	0.29	0.22–0.38	<0.01
	AT	Non-use	1.0			1.0		
		Current use of SGLT2i	0.35	0.30–0.41	<0.01	0.25	0.21–0.31	<0.01
		Recent use of SGLT2i	1.08	0.75–1.55	0.69	1.17	0.57–2.41	0.67
		Past use of SGLT2i	1.21	0.97–1.51	0.09	1.37	0.79–2.39	0.26
	Severe Renal Disease	ITT	Non-initiator	1.0			1.0	
SGLT2i initiator			0.55	0.46–0.67	<0.01	0.78	0.48–1.28	0.32
OT		Non-initiator	1.0			1.0		
		SGLT2i initiator	0.34	0.25–0.47	<0.01	0.37	0.18–0.74	0.01
AT		Non-use	1.0			1.0		
		Current use of SGLT2i	0.31	0.24–0.40	<0.01	0.36	0.21–0.64	<0.01
		Recent use of SGLT2i	0.70	0.38–1.32	0.27	0.37	0.19–0.71	<0.01
		Past use of SGLT2i	0.82	0.58–1.17	0.28	0.56	0.37–0.85	0.01
CV		ITT	Non-initiator	1.0			1.0	
	SGLT2i initiator		0.75	0.61–0.93	0.01	0.79	0.49–1.27	0.32
	OT	Non-initiator	1.0			1.0		
		SGLT2i initiator	0.54	0.40–0.74	<0.01	0.61	0.24–1.58	0.31
	AT	Non-use	1.0			1.0		
		Current use of SGLT2i	0.76	0.61–0.95	0.02	0.84	0.52–1.33	0.45
		Recent use of SGLT2i	1.62	0.95–2.78	0.08	1.95	0.79–4.85	0.15
Past use of SGLT2i	1.19	0.78–1.81	0.41	0.94	0.57–1.56	0.81		
MI	ITT	Non-initiator	1.0			1.0		
		SGLT2i initiator	0.98	0.74–1.28	0.86	1.19	0.65–2.19	0.58
	OT	Non-initiator	1.0			1.0		
		SGLT2i initiator	0.67	0.45–0.99	0.05	0.98	0.31–3.04	0.97

		Main analysis			IPTW analysis			
		Exposure	HR*	95% CI	p value	HR†	95% CI	p value
IS	AT	Non-use	1.0			1.0		
		Current use of SGLT2i	0.94	0.71–1.25	0.67	1.19	0.63–2.24	0.59
		Recent use of SGLT2i	1.92	0.97–3.77	0.06	2.81	0.87–9.06	0.08
		Past use of SGLT2i	1.05	0.57–1.94	0.88	0.99	0.46–2.17	0.99
	ITT	Non-initiator	1.0			1.0		
		SGLT2i initiator	0.51	0.36–0.74	<0.01	0.38	0.22–0.66	<0.01
	OT	Non-initiator	1			1		
		SGLT2i initiator	0.37	0.21–0.65	<0.01	0.21	0.11–0.37	<0.01
AT	Non-use	1.0			1.0			
	Current use of SGLT2i	0.57	0.39–0.83	<0.01	0.51	0.32–0.83	0.01	
	Recent use of SGLT2i	1.11	0.41–3.01	0.84	0.83	0.27–2.56	0.75	
	Past use of SGLT2i	1.24	0.66–2.31	0.50	0.86	0.44–1.69	0.67	

Reference group=non-initiator/non-use.

*Adjusted estimates obtained using a Cox proportional hazard regression model including all variables in **Supplementary table 1**.